Table 1. Overview on DC-based immunotherapy in ovarian cancer.

Author and year	TAA	Type of immunotherapy	N°	Clinical outcome
Brossart 2000	MUC1 or HER2	DCs + peptide	3	1/3 SD > 8 mo; 1/3 SD during 8 weeks
Hernando 2002	Tumor cell lysate	DCs + tumor cell lysates and KLH	6	3/6 SD
Loveland 2006	Mannan-MUC1 fusion protein	DCs + peptide	1	SD
Homma 2006	Tumor cells	DC/tumor cell fusions + rhIL-12	4	1 PD with temporary decrease of CA125
Hernando 2007	α-FR	DCs + α-FR-coding mRNA	1	PRs
Peethambaram 2009	HER2	Mix of PBMCs and DCs + recombinant HER2-based fusion protein	4	2/4 SD
Chu 2012	HER2 + TERT + PADRE	DCs + peptides +/− cyclophosphamide 2 d prior to vaccination + pneumococcal vaccine	11	2/11 PD during vaccination, 3/11 PD between 6–26 mo, 6/11 CR
Rhama 2012	p53	Peptide + IL-2 s.c. vs. DCs + peptide + IL-2 i.v.	21	4/20 NED after 2 y, 16/20 PD (mean 7 mo)
Kandalaft 2013	Tumor cell lysate	A. In 6 patients: bevacizumab i.v. + metronomic cyclophosphamide p.o., followed by bevacizumab plus vaccination with DCs pulsed with tumor cell lysates B. In 3/6 patients, this was continued with lymphodepletion followed by the transfer of autologous vaccine-primed T-cells in combination with the vaccine	6	A. 2/6: PR, 2/6: SD, 2/6: PD B. 1/3: PR, 1/3: SD, 1/3: 1/3: PD
Coosemans 2013	WT1	DCs + WT1-coding mRNA	2	PD, but prolonged OS after subsequent chemotherapy

Abbreviations: CR, complete response; DC, dendritic cell; IL, interleukin; KHL, keyhole limpet hemocyanin; MUC1, mucin 1; NED, no evidence of disease; PBMC, peripheral blood mononuclear cell; OS, overall survival; PD, progressive disease; PR, partial remission; rh, recombinant human; SD, stable disease; TAA, tumor-associated antigen; TERT, telomerase reverse transcriptase; WT1, Wilms' tumor gene 1; y, years; mo, months; s.c., subcutaneous; i.v., intravenous; p.o., per oral; HER-2, human epidermal growth factor 2; PADRE,  DR-restricted Th helper epitope.